Cochrane · systematic review · CD008907
Eslicarbazepine acetate add‐on therapy for drug‐resistant focal epilepsy
Chang, X-C, Yuan, H, Wang, Y, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 6 · 100%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyEslicarbazepine acetate add‐on for drug‐resistant focal epilepsy
Population: people with drug‐resistant focal epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
≥ 50% reduction in seizure frequency (adults) | RR 1.71 [1.42, 2.05] | 5 studies · 1799 participants | Moderate Downgraded: risk of bias, inconsistency |
≥ 50% reduction in seizure frequency (children aged 6–18 years) | RR 1.35 [0.98, 1.87] | 2 studies · 322 participants | Moderate Downgraded: risk of bias |
Freedom from seizures | RR 3.16 [1.73, 5.78] | 6 studies · 1922 participants | Moderate Downgraded: risk of bias |
Treatment withdrawal (any reason) | RR 1.25 [0.93, 1.7] | 7 studies · 2185 participants | Moderate Downgraded: risk of bias |
Treatment withdrawal (adverse effect) | RR 2.72 [1.66, 4.46] | 7 studies · 2185 participants | Moderate Downgraded: risk of bias |
Adverse effects | no estimate extracted | NR | Moderate Downgraded: risk of bias |
Eslicarbazepine acetate add‐on for drug‐resistant focal epilepsy
Population: people with drug‐resistant focal epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
≥ 50% reduction in seizure frequency | RR 1.71 [1.42, 2.05] | 5 studies · 1799 participants | Moderate |
Freedom from seizures | RR 2.9 [1.49, 5.68] | 5 studies · 1799 participants | Moderate |
Treatment withdrawal (any reason) | RR 1.29 [1.06, 1.58] | 5 studies · 1799 participants | Moderate |
Treatment withdrawal (adverse effect) | RR 2.66 [1.42, 4.96] | 5 studies · 1799 participants | Moderate |
Adverse effects | no estimate extracted | NR | Moderate |
Eslicarbazepine acetate compared to placebo for drug‐resistant partial epilepsy
Population: patients with drug‐resistant partial epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
People who had 50% reduction in seizures patient diaries Eslicarbazepine acetate vs placebo | RR 1.86 [1.46, 2.36] | 4 studies · 1146 participants | High |
Treatment withdrawal (any reason) clinical observation Eslicarbazepine acetate vs placebo | RR 1.07 [0.73, 1.57] | 4 studies · 1146 participants | Low |
Treatment withdrawal(adverse effect) Clinical oberservation Eslicarbazepine acetate vs placebo | RR 2.26 [0.98, 5.21] | 4 studies · 1146 participants | Low Downgraded: imprecision |
Seizure free Patient diary Eslicarbazepine acetate vs placebo | RR 3.04 [1.44, 6.42] | 4 studies · 1146 participants | Low Downgraded: imprecision |
dizziness Patient reports and Clinical observation Eslicarbazepine acetate vs placebo | RR 3.09 [2.01, 4.75] | 4 studies · 1146 participants | Moderate |
nausea Patient reports and Clinical observation Eslicarbazepine acetate vs placebo | RR 3.06 [1.38, 6.81] | 3 studies · 744 participants | Low Downgraded: imprecision |
diplopia Patient reports and Clinical observation Eslicarbazepine acetate vs placebo | RR 3.73 [1.57, 8.86] | 3 studies · 1049 participants | Low Downgraded: imprecision |